Peptide Legal Status and Long-Term Health Risks

Why legal status matters for long-term health

Most discussions of peptide law ask whether a user can get in trouble. For long-term health, a different question matters more: does anyone have to show that a product is safe over years of use? For an approved prescription medicine, the answer is yes. The sponsor has to run trials, follow manufacturing rules and report adverse events after approval. For a vial sold "for research use only," nobody carries those duties.

That gap is a large part of why the evidence in our overview of long-term peptide health effects is so thin. No company selling BPC-157 or TB-500 online is obliged to run a two-year safety study, so none has. This page summarizes rules and enforcement as we found them in published sources. It isn't legal advice, and several of the rules changed in 2026.

What "research use only" means under US law

As of October 2026, none of the peptides discussed here (BPC-157, TB-500, CJC-1295, ipamorelin, GHRP-2, GHRP-6, IGF-1 LR3 and AOD-9604) is an FDA-approved drug. Sermorelin was approved in the past, which matters for compounding.

The FDA decides whether a product is a drug by its intended use, judged from the seller's website and marketing as well as the label. Its August 24, 2026 warning letter to the online seller Peak Performance Peptides spells this out. Despite "research use only" and "not for human consumption" labels, the agency said the website showed the products were intended as drugs for human use. It cited product claims and the seller's marketing of bacteriostatic water for reconstitution, which it described as providing the means to prepare an injectable drug. The letter treated the products as unapproved new drugs.

Criminal cases are rarer. In July 2026 a federal judge sentenced Matthew Kawa, who ran Paradigm Peptides, to 70 months in prison. According to CBS News, he had pleaded guilty to selling unapproved drugs and importing them illegally, and the judge found that the company's products had been adulterated with steroids.

Both actions targeted sellers. The records we reviewed didn't include a case against an individual buyer for personal use, and we haven't tried to describe penalties that might apply to one. Little enforcement against buyers still isn't legal permission: the FDA's import guidance, covered below, says importing an unapproved new drug is illegal.

The health side of the label

A "not for human consumption" label also takes a product outside the system that checks sterility and purity for human use. The FDA's compounding safety notes show what that leaves open. For BPC-157, the agency flags a possible risk of immunogenicity (an immune response against the peptide) and complexities with peptide-related impurities, and says it found no or only limited safety information for the proposed routes. For the TB-500 fragment, it found no human exposure data at all.

Those notes concern products made by licensed pharmacies, and research-use vials get less oversight than that. Nobody in a research-use supply chain is required to answer the questions FDA raises, even though they're the ones that matter most for months or years of use.

Prescriptions and compounding: what is actually lawful

Clinics often present prescription peptides as the legal alternative to research-use vials. As of October 2026, that holds for fewer compounds than many clinic websites suggest.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy can compound with a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Sermorelin qualifies because it was the active ingredient in Geref. The FDA withdrew Geref's approvals in 2009 at the manufacturer's request and determined in 2013 that it wasn't withdrawn for safety or effectiveness reasons. A 2026 analysis by the law firm Golds & Friedberg concludes that sermorelin can be compounded under 503A on that basis. It's the only growth hormone-releasing peptide on this page with that pathway. Our sermorelin profile covers how little adult evidence there is.

Ipamorelin and CJC-1295 have no lawful 503A route. Their nominations were withdrawn in late 2024, and the FDA's Pharmacy Compounding Advisory Committee (PCAC) then voted against adding them to the bulks list. The FDA still lists ipamorelin acetate in Category 2 for 503B outsourcing facilities, citing serious adverse events, including death, in an intravenous study. For CJC-1295 it cites increased heart rate and a systemic vasodilatory reaction. A compounded CJC-1295 and ipamorelin blend is not the legitimate prescription route it's often marketed as.

BPC-157 and TB-500 changed status in 2026, though not in the way some vendors imply. In April 2026 the FDA removed 12 peptides from Category 2 (substances that may present significant safety risks) after their nominations were withdrawn, and its page now lists BPC-157 and the TB-500 fragment as "nominated but withdrawn." The law firm Orrick notes that removal doesn't place a substance on the bulks list or in Category 1, where FDA allows compounding under enforcement discretion. The PCAC met on July 23-24, 2026 to consider adding BPC-157, TB-500 and five other peptides. Its votes are non-binding, and as of October 2026 the FDA hasn't proposed a rule adding any of them. Removal from Category 2 is not permission to compound.

A lawful prescription brings a licensed pharmacy and a prescriber who can order blood work. It doesn't create long-term data that never existed. Geref was approved as a diagnostic test and for growth hormone deficiency in children, not for adults using sermorelin for body composition or recovery.

Importing peptides and crossing borders

The FDA's personal importation page says an unapproved new drug is illegal to import. Staff may use discretion in limited situations. For a product treating a serious condition, the listed conditions include a written personal-use statement, generally no more than a three-month supply, and the name of a US-licensed doctor responsible for treatment. A peptide ordered from an overseas website for training recovery fits those conditions poorly, and nothing in the policy makes domestic research-use sales lawful.

Other regulators take a similar line. Health Canada's April 2026 advisory lists BPC-157, CJC-1295, ipamorelin and TB-500 among unauthorized injectable peptides it has seized, and says "For Research Use Only" labeling doesn't make products legal. We didn't review customs rules country by country.

Tested athletes and the WADA list

For athletes in sports that follow the World Anti-Doping Code, the WADA Prohibited List matters more than FDA status. As of October 2026, the 2026 List is in force (since January 1, 2026), and every peptide below is prohibited at all times, in and out of competition.

WADA has also published its 2027 List, effective January 1, 2027. According to USADA, it names "peptides" in general as prohibited in the S0 class, so a peptide that isn't named may still be prohibited.

A prescription doesn't change an athlete's status on its own. USADA explains that an athlete who needs a prohibited medication can apply for a Therapeutic Use Exemption (TUE), and that testing positive without one can lead to a sanction. Athletes are strictly liable for what's in their systems, so a mislabeled or contaminated vial is still the athlete's responsibility. We don't cover sanction lengths here. The pressures tested athletes describe are covered in our piece on the psychological side of peptide use.

Medical records, monitoring and disclosure

Because most of these peptides are bought outside the medical system, long-term use often happens without anyone watching the relevant blood work. That matters most for compounds that raise growth hormone and IGF-1. Trial data and FDA reviews have recorded higher blood sugar with ipamorelin and GHRP-6, and a 2006 study found IGF-1 above the normal range at the highest CJC-1295 dose tested. Our comparison of peptides and anabolic steroids looks at how these markers compare with steroid risks.

Telling a doctor about research-use peptides puts that use in the medical record, but it also lets the doctor read lab results in context. Insurance applications commonly ask about medications and drug use, and how an insurer treats undisclosed peptide use depends on the policy and the jurisdiction. We didn't research privacy law or insurer rules for this page.

What to watch next

The FDA may publish a proposed rule on the peptides the PCAC reviewed in July 2026, and Orrick reports that a second PCAC meeting on other peptides is planned before the end of February 2027. The 2027 WADA List takes effect January 1, 2027. Neither change would produce long-term human safety data. A place on the 503A bulks list would let licensed pharmacies compound a peptide for individual patients, but it wouldn't show that years of use are safe.